2025 UICMEW | January 29, 2025 Pre-Test UICMEW | Pre-Test Session 3 Name * Name First First Last Last Email * 1. Which of the following best describes a limitation of current registrational studies in addressing racial disparities in oncology? * A. Minority populations are overrepresented in clinical trials. B. Minority populations often face barriers to participation, leading to underrepresentation. C. Clinical trials do not require FDA guidance on racial diversity. D. All patients in registrational studies receive the same treatment, regardless of racial background. 2. Which of the following best explains the mechanism of action of antibody-drug conjugates (ADCs)? A. ADCs utilize immune checkpoint inhibition to enhance T-cell activity. B. ADCs deliver chemotherapy to targeted cells via a monoclonal antibody linked to a cytotoxic agent. C. ADCs use radiolabeled isotopes to localize cancer cells for destruction. D. ADCs employ gene editing to modify cancer cell DNA and prevent proliferation. 3. Which of the following emerging diagnostics is used for early cancer detection and monitoring of minimal residual disease (MRD)? A. Immunohistochemistry (IHC) B. Liquid biopsy C. Flow cytometry D. Whole-genome sequencing 4. Which of the following is a key indication for adoptive cell therapy in oncology? A. Colon cancer with high microsatellite instability B. Early-stage lung cancer C. Metastatic melanoma D. Prostate cancer with localized disease 5. Why is addressing health equity important in clinical trials for oncology treatments? A. It ensures all patients receive identical treatments, regardless of disease severity. B. It improves access and representation of diverse populations, leading to more generalizable and effective treatments. C. It minimizes the costs of conducting clinical trials in underserved regions. D. It accelerates the approval process for new treatments by reducing trial diversity. Case: A 58-year-old African American female presents to the oncology clinic with newly diagnosed metastatic non-small cell lung cancer (NSCLC). Her medical history includes hypertension and type 2 diabetes, both well-controlled. Molecular testing reveals high PD-L1 expression and no actionable mutations. She expresses interest in clinical trial participation but is concerned about the potential risks and whether she would qualify. 6. Which of the following would be the most appropriate next step in managing this patient’s case while addressing health equity and clinical trial participation? A. Recommend standard chemotherapy and radiation without discussing clinical trial options due to potential risks. B. Enroll the patient in a trial immediately, as all minority patients should be prioritized for inclusion. C. Review available clinical trials, ensuring they include diverse populations and align with the patient’s treatment goals and molecular profile. D. Begin treatment with immunotherapy alone, as PD-L1 expression suggests efficacy, without considering clinical trials. Submit If you are human, leave this field blank. Δ